Oster M, Enders S, Samuels S, Cone L, Hooton T, Browder H, Flynn N; International Conference on AIDS.
Int Conf AIDS. 1993 Jun 6-11; 9: 528 (abstract no. PO-B36-2360).
University of California, Davis.
OBJECTIVE: To evaluate the effect of a liquid formulation of high-dose megestrol acetate (MA) (800 mg/day) on body weight, body composition, caloric intake, mental attitude and medical evaluation in patients with CDC-defined AIDS. METHODS: Multi-center, double-blind, randomized, placebo-controlled study involving 100 patients with AIDS and severe cachexia. Patients had documented weight loss of > or = 10% of ideal body weight. They were randomly assigned to placebo (N = 48) or MA (N = 52) and were evaluated monthly for 12 weeks. RESULTS: MA-treated patients had significantly increased sense of well-being, caloric intake and body weight compared to placebo-treated patients. Body composition analyses showed that the weight gain associated with MA treatment was due primarily to a gain in fat mass. At weeks 8 and 12, MA-treated patients had a significant increase in mean CD4 count compared to placebo-treated patients (mean increase 69/mm3). Other laboratory parameters remained within the normal ranges for both treatment groups. Side effects were minimal and comparable in the two groups. CONCLUSIONS: This study demonstrates that this new formulation of megestrol acetate is well-tolerated, simulates appetite, increases food intake, and results in body weight gain and increased sense of well-being in AIDS patients.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Appetite
- Appetite Stimulants
- Body Composition
- Body Weight
- CD4 Lymphocyte Count
- Cachexia
- Double-Blind Method
- Eating
- Energy Intake
- Humans
- Megestrol Acetate
- Nutritional Status
- Placebos
- Weight Gain
- Weights and Measures
Other ID:
UI: 102205371
From Meeting Abstracts